Lipocine Inc is a biopharmaceutical company focused on the development of innovative products for the treatment of metabolic and endocrine disorders, primarily leveraging its proprietary drug delivery technologies. The company is engaged in creating and advancing formulations that aim to improve the efficacy and bioavailability of therapeutic agents, with a key emphasis on addressing conditions such as testosterone deficiency. Lipocine's mission revolves around enhancing patient outcomes through its novel approaches to drug development, making it a significant player in the evolving field of hormonal therapies. Read More
DALLAS, Texas, October 8, 2026 — Algorhythm Holdings, Inc. (NASDAQ: RIME) has introduced Azure P2P™, a renewable power-generation process designed to convert low-value forest wood into around-the-clock electricity for data centers, utilities and industrial facilities . The announcement adds a technology milestone to the company’s ongoing restructuring, which is focused on reducing reliance on dilutive financing, improving access to capital and expanding profitable revenue.
Lipocine Inc (NASDAQ: LPCN) shares are trading higher after the company released topline results from a Phase 2 clinical study of LPCN 1148, an oral candidate under development for the
Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.
